Webinar replay

Partner of Choice. By Choice. How AbbVie Topped the Partnering 2030 Survey

Download the Partner'23 eBook now

In 2022 Inova surveyed more than 100 biotechs worldwide for its Partnering 2030 report​ to determine which pharma company offered the very best partnering experience. The clear winner: AbbVie. Praised by biotechs for its good working relationships and commitment to achieving business and scientific objectives, AbbVie has established itself as a partner of choice – and it’s not by accident. ​

In this exclusive webinar, Niels Emmerich, Vice President and Global Head of Search & Evaluation, explains how AbbVie chose to position itself as a partner of choice for biotechs, the best practices it implemented to achieve this position, and what the company is seeking in partners in 2023 and beyond.​ ​

Watch the replay to learn:​

  • How important the 'first touch' is in biopharma partnering​
  • Effective strategies for getting your foot in the door at a top pharma company
  • What partnering opportunities AbbVie is seeking in 2023​
Watch this replay to get expert insights from our panelists:
Niels Emmerich
Niels Emmerich
Vice President, Global Head S&E
Caroline Edlund Toulemonde
Caroline Toulemonde
Chief Strategy Officer

Please complete the form below

All fields marked with a * are required.

By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.
Preview eBook

Partner’23: Data, Deals, and Directions

  • IPO Activity at 10 Year Lows. Number and value of IPOs bottom out.
  • Paying for Quality

    Median Upfront Cash & Equity by Stage at Signing with Large Cap Biopharma 2018-2022 ($M).

  • Top 5 Dealmakers. By Deal Count 2022.
Download the Partner'23 eBook now

About Inova

Inova accelerates the find, deal, and collaborate phases of biopharma partnering. Its market-leading platform is used by 60% of the world’s top 50 pharma companies to source and manage their opportunities efficiently, and its technology powers more than 50,000 partnering meetings each year at the world's most important biopharma partnering conferences, including the BIO International Convention.
With subsidiaries Labiotech and IN-PART, Inova reaches more than 100,000 readers in life sciences a month and connects a network of 6,500 industry players and academic organizations.